PMOS awareness month - is there a cure yet?

September is PMOS awareness month, a moment to look clearly at one of the most common hormonal conditions women face. PMOS (formerly PCOS) reaches far beyond the ovaries, shaping fertility, weight, mood, skin, and long-term heart and metabolic health. Awareness matters because most women who have it still do not know.

The condition also entered a new chapter in 2026, starting with a name that finally reflects what it does to the body. The science is moving quickly, and so is the way clinicians are trained to spot it.

How common is PMOS?

PMOS is the most common hormonal condition in women of reproductive age. The World Health Organization estimates that it affects around 10 to 13 percent of women, roughly one in eight, and many experts believe the real number is higher. Up to 70 percent of women who have it are never diagnosed. In many cases their symptoms were treated as separate problems rather than one connected condition.

The condition is also becoming more visible over time. Global tracking shows a steady rise in cases across the past three decades, driven by a mix of better recognition and real increases in metabolic risk. That trend is one reason a dedicated awareness month carries weight.

The distance between symptoms and diagnosis is wide for a reason. Many women see several clinicians and wait years before anyone connects the dots, often because their weight, acne, or irregular cycles were treated one at a time. Guidelines now flag this dissatisfaction and the need for better awareness as a problem in its own right. The delay is not harmless, because the metabolic risks build quietly while the label is missing.

Where PMOS shows up in the body

PMOS was long defined by irregular cycles and the look of the ovaries on a scan, but its reach is wider than that. Insulin resistance is common in women with PMOS, including in women at a healthy weight, which raises the long-term risk of type 2 diabetes, high blood pressure, and heart disease. The same hormonal shifts can drive acne, unwanted hair growth, thinning scalp hair, and changes in mood, with anxiety and depression more common than in women without the condition.

Insulin resistance sits at the center of a lot of this. When cells stop responding well to insulin, the body makes more of it, and that excess nudges the ovaries to produce more androgens and the body to store more fat, especially around the middle. Those two forces feed each other, which is part of why symptoms cluster and why weight can climb without an obvious change in habits. Risk also runs in families, and a personal or family history of type 2 diabetes raises the odds, though PMOS turns up across every body type and background.

For women noticing several of these signs together, PMOS care that looks at hormones and metabolism in one place tends to catch more than a single-symptom visit. Changes in a monthly cycle matter here too, and understanding what causes abnormal bleeding is a practical first step, since irregular bleeding is one of the earliest signals.

Left unaddressed, PMOS raises the odds of serious problems later, from type 2 diabetes and heart disease to changes in the uterine lining tied to long stretches without a period. Early detection is what makes prevention possible. That is the real point of an awareness month, to turn scattered symptoms into a question worth bringing to a clinician.

Treating PMOS Today

Cycle, skin, and hormones

Care for PMOS works best when it follows the woman's goals rather than a single template. For cycle regularity and androgen symptoms, combined birth control pills are still the first-line medication. Androgens are hormones like testosterone that all women make in small amounts, but in PMOS levels often run higher than usual. That excess can show up as androgen symptoms such as persistent acne, extra hair growth on the face, chest, or back, and thinning hair on the scalp. Insulin-sensitizers like metformin address the metabolic side. Newer GLP-1 medications, first developed for diabetes and weight, have helped some women with the metabolic features, though large trials specific to PMOS are still needed. The right mix is individual, and Weight Management support that treats hormones and metabolism together tends to hold up better than a generic plan.

Lifestyle

Weight and lifestyle changes are first-line care in international guidelines, not because weight is the whole story, but because they improve the metabolic engine underneath the condition. Research shows that even a modest loss of 5 to 10 percent of body weight can ease reproductive, metabolic, and psychological symptoms, and it is recommended as an early step for women carrying extra weight.

Food is one of the most practical levers. A pattern built on high-fiber vegetables, whole grains, lean protein, and healthy fats helps steady blood sugar and calm the insulin swings that drive many symptoms, which is the core idea behind a PMOS diet. Weight change with PMOS is also stubborn for real physiological reasons, not a lack of effort, and understanding PMOS weight gain makes a plan easier to stick with.

Movement helps on its own, even if your weight doesn't change. Both cardio and strength training improve how the body uses insulin. Sleep and stress matter more than people usually realize, too. Poor sleep and chronically high cortisol both worsen insulin resistance and abdominal weight. Sleep problems are also more common with PMOS, so screening for sleep apnea is sometimes part of care.

Supplements, with care

Supplements deserve a more cautious note. A few, including inositol, omega-3 fatty acids, and vitamin D where a woman is deficient, have modest evidence behind them, but the research is limited and quality varies widely across products. They are best treated as a possible add-on discussed with a clinician, not a replacement for care that addresses the condition at its root. Marketing around detox teas and miracle supplements has raced ahead of the evidence, so a plain-eyed view protects women better than any product promising a shortcut.

Fertility and pregnancy

Fertility is one area where PMOS is very treatable. Irregular or absent ovulation is a leading cause of trouble conceiving, but ovulation-inducing medications and close monitoring help many women build a family, which is the heart of PMOS fertility care. Because pregnancy with PMOS carries higher risks of gestational diabetes and high blood pressure, coordinated fertility support and prenatal monitoring matter from the start.

When lifestyle steps alone do not restore ovulation, clinicians often add medication. Metformin can improve cycle regularity, while ovulation-inducing drugs such as letrozole or clomiphene help trigger the release of an egg, alone or in combination. Care is matched to the individual rather than applied by default. Once pregnant, closer watching for gestational diabetes, high blood pressure, and preterm birth becomes part of the plan, and with that monitoring most women with PMOS go on to have healthy pregnancies.

Mood and the long term view

PCOS also affects mood and long-term health, so good care looks beyond the ovaries. Anxiety and depression are more common with PCOS, and Tia treats mental health support as an essential part of care rather than an afterthought, with therapy delivered through trusted external partners.

Body image and pressure around weight often travel with PMOS, partly because so much advice centers on the scale. Care that names that pressure, instead of adding to it, tends to hold up better over time. Support works best when it treats the whole person, mood and metabolism and fertility together, rather than reducing a woman to a number.

Can PMOS be cured?

Unfortunately, as of 2026 there is no cure for PMOS just yet. The more useful answer is that it is highly manageable today, and that research is moving faster than at any point in the condition's history. Several treatments now in the pipeline aim at the metabolic and hormonal roots of PMOS rather than only smoothing over symptoms. That progress is real, even as any product promising an outright cure still deserves real skepticism.

Experimental metabolic medications

Beyond the treatments available today, a handful of medications are being studied for their potential in PCOS.

The most talked-about leads are the metabolic medications already reshaping diabetes and weight care. GLP-1 receptor agonists and a related class called SGLT-2 inhibitors are being studied for their ability to improve insulin sensitivity and lower the high androgen levels tied to metabolic dysfunction. Early results are encouraging, though the strongest evidence still comes from diabetes and obesity rather than PMOS itself.

For women whose PMOS is driven strongly by insulin resistance and weight, these drugs appeal because they act on several problems at once, lowering blood sugar, easing appetite, and in some studies nudging cycles toward more regular timing. The open questions are how well the benefits last and how they play out in this specific group, especially for women who may become pregnant, since these medications are generally paused before conception. That is the kind of judgment a clinician who knows the full history is meant to weigh.

Combination therapy

Combination therapy is another frontier. A treatment known as SPIOMET, which pairs low doses of spironolactone, pioglitazone, and metformin, is being tested to correct the underlying metabolic and reproductive changes rather than only masking them, and early work suggests it may outperform standard birth control on some measures. There is still no medication approved specifically for PMOS, so these remain investigational.

Artemisinin (anti-malaria drug) for PMOS

One of the more surprising leads comes from an old malaria drug. Artemisinin and its derivatives lowered testosterone and improved ovulation in animal models by prompting the breakdown of CYP11A1, an enzyme that helps produce androgens, and a small pilot in 19 women showed similar drops in testosterone. The findings are early and need larger human trials before anything changes in the clinic.

That work points to a broader strategy. Rather than only managing symptoms, researchers are targeting the enzymes that build androgens in the first place, including proteins like CYP17A1, to turn down excess hormone production at the source. Most of this remains in laboratories and small studies rather than everyday care, but it marks a real shift in how PMOS is being approached.

A note on the hype

A protective note belongs here. The same metabolic drugs generating real research are also being marketed hard, often direct to consumers, ahead of the evidence in PMOS specifically. A medication being cleared or available is not the same as being proven for this condition, and the safest path pairs genuine innovation with a clinician who knows the full picture.

PMOS awareness month is a fitting time to hold both truths at once, that the science is finally catching up, and that steady, personalized care still does the heavy lifting. For women experiencing symptoms, questions, or next steps, booking a visit with a Tia clinician is a strong place to start. A series of conversations that look at hormones, metabolism, mood, and goals together can turn years of scattered symptoms into one clear plan.

The Tia approach to treating PMOS

This whole-person approach is where Tia's care model is built to help. Tia'sCare Model is designed to catch what standard primary care often misses, connecting gynecology, primary care, metabolic, and mental health into one Care Plan, and drawing on partnerships with Cedars-Sinai, UCSF Health, and Dignity Health. For women whose symptoms have never added up, Hormonal Imbalance care that treats the systems together is often the turning point.

References

1. World Health Organization. (2025). Polycystic ovary syndrome. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome

2. Zheng, X., et al. (2025). Global burden of polycystic ovary syndrome in women of reproductive age, 1990-2021: Analysis of the global burden of disease study 2021 with projections to 2050. PLOS ONE. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503323/

3. Endocrine Society. (2026). PCOS renamed PMOS. https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change

4. STAT News. (2026). PCOS is now called PMOS, Polyendocrine Metabolic Ovarian Syndrome. STAT. https://www.statnews.com/2026/05/12/pcos-now-called-pmos-polyendocrine-metabolic-ovarian-syndrome/

5. American Journal of Managed Care. (2026). PCOS renamed PMOS in landmark shift reflecting metabolic and endocrine features. AJMC. https://www.ajmc.com/view/pcos-renamed-pmos-in-landmark-shift-reflecting-metabolic-and-endocrine-features

6. University of Colorado Anschutz Medical Campus. (2026). PCOS gets a new name. https://news.cuanschutz.edu/news-stories/pcos-new-name

7. Teede, H. J., et al. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447-2469. https://academic.oup.com/jcem/article/108/10/2447/7242360

8. Lie Fong, S., Douma, A., & Verhaeghe, J. (2020). Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): How to achieve weight loss in overweight and obese women with PCOS? Journal of Gynecology Obstetrics and Human Reproduction. https://www.sciencedirect.com/science/article/abs/pii/S2468784720302518

9. CNN Health. (2026). PCOS name change to PMOS and what it means. CNN. https://www.cnn.com/2026/05/13/health/pcos-name-change-pmos-wellness

10. Garcia-Beltran, C., et al. (2023). SPIOMET4HEALTH: Efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome. Trials, 24, 589. https://pmc.ncbi.nlm.nih.gov/articles/PMC10503102

11. Liu, Y., et al. (2024). Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction. Science, 384(6701), eadk5382. https://www.science.org/doi/10.1126/science.adk5382

12. Wu, X., Yi, W., & Liu, X. (2026). Precision targeted therapy for PCOS: Emerging drugs, translational challenges, and future opportunities. Biomedicines, 14(1), 213. https://pmc.ncbi.nlm.nih.gov/articles/PMC12839070/